Eastman Chemical Company filings document regulatory disclosures for a global specialty materials issuer with publicly traded common stock and outstanding debt securities. Form 8-K reports furnish quarterly and annual operating results, including sales, EBIT, cash flow, segment performance, price-cost conditions, raw-material pressures and updates tied to specialty businesses and methanolysis assets.
Proxy materials describe director elections, board committee matters, executive compensation, say-on-pay voting and shareholder proposals. Other material-event filings record debt issuance under registration statements and indentures, officer and director changes, compensatory arrangements, common stock references and note terms, including interest, maturity and redemption provisions.
Eastman Chemical senior vice president Adrian James Holt received an equity award linked to company performance. On 02/11/2026, Holt acquired 2,297 shares of Eastman Chemical common stock at a price of $0 per share. These shares were granted following the determination of performance shares earned for the three-year 2023–2025 performance period, and are held as direct beneficial ownership.
Eastman Chemical Company reports 2025 full-year results and outlines its strategy as a global specialty materials company. Sales revenue reached $8.8 billion, with EBIT of $776 million, net earnings attributable to Eastman of $474 million, and diluted EPS of $4.10. Net cash from operating activities was $970 million.
The company emphasizes an innovation-driven growth model, focusing on specialty polymers, films, additives, intermediates, and fibers across four segments. It highlights molecular recycling and “Renew” branded products, with its polyester molecular recycling facility generating about 2.5 times more output than 2024. Around 55% of 2025 sales came from outside the United States and Canada.
Eastman Chemical CEO and Board Chair Mark J. Costa reported an insider equity transaction involving company stock on February 4, 2026. He exercised 48,649 employee stock options at an exercise price of $65.16 per share, receiving the same number of Eastman Chemical common shares.
A portion of these shares, 43,638, was withheld by Eastman Chemical to cover the option exercise price and tax withholding obligations in a net exercise, which the filing states does not represent a sale by Costa. After these transactions, Costa directly owned 458,997 shares of common stock, with an additional 3,231 shares held indirectly through an ESOP.
Eastman Chemical Company’s EVP and CFO, William Thomas McLain Jr., reported an option-related share transaction. On 02/04/2026 he exercised employee stock options for 3,013 shares of common stock at an exercise price of $65.16 per share.
To cover the option exercise price and tax withholding in a “net exercise,” 2,636 shares were withheld by Eastman Chemical and not sold on the market. After these transactions, he directly beneficially owned 53,901 shares of Eastman Chemical common stock.
A shareholder of EMN has filed a Rule 144 notice to sell 6,016 common shares through Fidelity Brokerage Services LLC on or about 02/04/2026, to be sold on the NYSE with an aggregate market value of $475,011.96.
The shares come from restricted stock that vested as compensation on 02/19/2021, 10/15/2022, and 02/15/2023, in amounts of 2,249, 1,040, and 2,727 shares. Shares outstanding were 114,069,800 at the time of the notice; this is a baseline figure, not the amount being sold.
Eastman Chemical Company filed a current report to furnish its financial results for the fourth quarter of 2025. The company states that it publicly released these results on January 29, 2026, and has attached the full earnings press release as an exhibit.
The earnings release is provided as Exhibit 99.01 and is incorporated by reference, but is designated as “furnished” rather than “filed” under securities law, which affects how it is treated for certain legal liabilities and future regulatory filings.
Eastman Chemical Company reported an equity award to executive officer Stephen G. Crawford, EVP, Technology Projects. On 01/02/2026, he received 34,193 restricted stock units (RSUs), each representing a contingent right to receive one share of Eastman Chemical common stock. These RSUs were reported as derivative securities beneficially owned directly.
The RSUs carry a conversion price of $0 and are scheduled to vest and pay out in unrestricted shares of common stock on February 2, 2027, subject to Mr. Crawford’s continued employment. After this grant, he beneficially owns 34,193 derivative securities in the form of RSUs tied to Eastman Chemical common stock.
BlackRock, Inc. has filed an amended Schedule 13G reporting a significant passive ownership position in Eastman Chemical Co common stock. As of the event date of 11/30/2025, BlackRock reports beneficial ownership of 13,598,433 shares, representing 11.9% of Eastman Chemical’s outstanding common stock. BlackRock has sole voting power over 13,254,753 of these shares and sole dispositive power over all 13,598,433 shares, with no shared voting or dispositive power.
The filing is made on a passive basis, with BlackRock certifying the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Eastman Chemical. The filing notes that one underlying holder, iShares Core S&P Small-Cap ETF, has an interest in more than five percent of Eastman Chemical’s outstanding common stock.
Eastman Chemical (EMN) executive Stephen G. Crawford, EVP, Technology Projects, filed an initial statement of beneficial ownership. He reports 60,301 shares of common stock held directly, plus indirect holdings through retirement plans and spouse accounts.
He also lists employee stock options covering multiple grants, including 24,527 shares at $86.15 expiring 02/26/2034 and 25,883 shares at $83.84 expiring 02/23/2033. Vesting schedules note one‑third becoming exercisable on specified dates in 2025–2027 for recent grants.
Eastman Chemical (EMN) reported weaker Q3 2025 results. Sales were $2,202 million versus $2,464 million a year ago, and earnings before income taxes were $134 million versus $280 million. Net earnings were $47 million, with diluted EPS of $0.40 compared to $1.53.
Segment performance softened: total segment Adjusted EBIT was $249 million versus $407 million, with declines in Advanced Materials ($53 million vs $122 million), Chemical Intermediates ($1 million vs $43 million), and Fibers ($67 million vs $112 million). Additives & Functional Products was $128 million versus $130 million. The effective tax rate rose to 65%, reflecting impacts from the One Big Beautiful Bill Act and uncertain tax positions.
Year-to-date cash from operations was $468 million, capital expenditures $434 million, and net interest expense $156 million. Total borrowings were $5,075 million, including $290 million of commercial paper. Environmental reserves increased to $322 million. The company received $14 million of DOE reimbursements tied to a terminated grant related to the Longview, Texas recycling project.